Focusing on the Genes that Matter Most: 10x Genomics Launches Targeted Gene Expression Solution
May 20 2020 - 9:00AM
Building on its earlier reveal at the Advances in Genome Biology
and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq:
TXG) today launched its Targeted Gene Expression Solution for
single cell and shortly following for spatial genomic research.
Targeted Gene Expression gives scientists the ability to focus
their research on the cell types and biomarkers that matter most to
their research, enabling them to answer biological questions
quickly and efficiently.
“Our Targeted Gene Expression Solution provides customers the
option to progress from unbiased discoveries to more focused
research questions by looking at a subset of genes of interest,
which can increase sample throughput, streamline data analysis, and
reduce sequencing and computational burdens,” said Ben Hindson,
Co-founder, President and Chief Scientific Officer of 10x Genomics.
“By focusing on the genes that matter most, researchers can
ultimately bring better treatments and therapeutics through
clinical trials more efficiently.”
This approach also captures unique gene expression signatures,
probes disease and drug targets and allows for the discovery of
mechanisms through which small molecules act. Using this
technology, researchers can measure the effects of activation or
inhibition of signalling pathways. In addition, it also allows the
scientific community to dissect signalling pathways using targeted
CRISPR screens.
“10x-targeted single-cell RNA sequencing will allow us to focus
on the expression of relevant immuno-oncology genes, streamline our
data analysis and reduce our sequencing costs,” said Aude Chapuis,
M.D., Assistant Member, Program in Immunology Clinical Research
Division, Fred Hutchinson Cancer Research Center.
10x’s Targeted Gene Expression Solution benefits from a list of
comprehensive pre-designed gene panels that are relevant for
different research areas, including cancer, immunology,
neuroscience and various disease and drug targeting applications.
This technology is also customizable for individualized research
goals, improving experimental efficiency while maintaining high
gene sensitivities. A 10x Custom Panel Designer, which will be
released later this year, will enable customers to either add on
genes to existing panels or create fully custom panels.
“Target enrichment of informative transcripts balances costs
with biological insight,” added Joseph Replogle, Weissman Lab,
UCSF, “and enables users to easily adapt the 10x Genomics platform
to their question of interest."
The Targeted Gene Expression Solution is available for
pre-orders beginning today. In conjunction with the announcement,
10x Genomics is offering a webinar to help researchers better
understand how their research could benefit from Targeted Gene
Expression. To learn more, visit
10xgenomics.com/products/targeted-gene-expression.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 860 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
740 issued patents and patent applications.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negatives of these terms or
variations of them or similar terminology. These forward-looking
statements include statements regarding 10x Genomics, Inc.’s
current and upcoming products and solutions, which involve risks
and uncertainties that could cause actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. These statements are based on
management’s current expectations, forecasts, beliefs, assumptions
and information currently available to management, and actual
outcomes and results could differ materially from these statements
due to a number of factors. These and additional risks and
uncertainties that could affect 10x Genomics, Inc.’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics, Inc. files with the Securities and Exchange
Commission from time to time. The forward-looking statements in
this press release are based on information available to 10x
Genomics, Inc. as of the date hereof, and 10x Genomics, Inc.
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing 10x Genomics, Inc.’s
views as of any date subsequent to the date of this press
release.
Disclosure Information10x Genomics uses filings
with the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsInvestors:investors@10xgenomics.comMedia:media@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024